Julien Couture-Senécal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julien Couture-Senécal has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Omar F. Khan
Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario M5S 3G9, Canada
6 shared publications - Grayson Tilstra
Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario M5S 3G9, Canada
5 shared publications - Janice Pang
Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario M5S 3G9, Canada
4 shared publications - Yan Ming Anson Lau
Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario M5S 3G9, Canada
4 shared publications - Alanna M. Manning
Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario M5S 3G9, Canada
2 shared publications - Karlene L. M. Knaggs
Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario M5S 3G9, Canada
2 shared publications
Latest Publications
- 10 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (928) , eadx2924
Human and mouse long noncoding RNAs reengineered for exogenous delivery reduce LPS-induced inflammation in human macrophages and mice
Long noncoding RNAs (lncRNAs) constitute a substantial portion of the transcriptome and outnumber protein-coding transcripts in humans. lncRNA molecules are bioactive and control cellular and systemic functions by directly or indirectly regulating gene expression at the transcriptional or posttranscriptional levels. Here, we established the use of lncRNA as a modality to treat disease by reengineering three lncRNAs—GAPLINC, MIST, and DRAIR—to treat acute inflammation in mice and human macrophages. For each lncRNA, we established an in vitro transcription synthesis and high-performance liquid chromatography purification workflow and optimized the lncRNA isoforms, 5′ cap, 3′ poly(A) tail, and chemical base modifications to improve specificity and performance. We also optimized the in vivo delivery of lncRNA with a lipid nanoparticle system that did not induce confounding effects. Using this pipeline and delivery platform, we demonstrated that each lncRNA reduced lipopolysaccharide (LPS)–induced inflammation by specifically regulating distinct subsets of cytokines in cultured mouse macrophages and in mice. GAPLINC and DRAIR reduced the transcription of IL-1β and IL-6, respectively, whereas MIST attenuated TNFα production posttranscriptionally. In addition, we showed that reengineered GAPLINC reduced LPS-induced inflammation in human monocytes, suggesting the clinical potential of this approach. Our engineering approach and findings establish a previously unidentified nucleic acid modality and demonstrate an effective way to reengineer regulatory lncRNAs to treat disease.
- 10 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 19 (928) , eadx2924
Human and mouse long noncoding RNAs reengineered for exogenous delivery reduce LPS-induced inflammation in human macrophages and mice
Long noncoding RNAs (lncRNAs) constitute a substantial portion of the transcriptome and outnumber protein-coding transcripts in humans. lncRNA molecules are bioactive and control cellular and systemic functions by directly or indirectly regulating gene expression at the transcriptional or posttranscriptional levels. Here, we established the use of lncRNA as a modality to treat disease by reengineering three lncRNAs—GAPLINC, MIST, and DRAIR—to treat acute inflammation in mice and human macrophages. For each lncRNA, we established an in vitro transcription synthesis and high-performance liquid chromatography purification workflow and optimized the lncRNA isoforms, 5′ cap, 3′ poly(A) tail, and chemical base modifications to improve specificity and performance. We also optimized the in vivo delivery of lncRNA with a lipid nanoparticle system that did not induce confounding effects. Using this pipeline and delivery platform, we demonstrated that each lncRNA reduced lipopolysaccharide (LPS)–induced inflammation by specifically regulating distinct subsets of cytokines in cultured mouse macrophages and in mice. GAPLINC and DRAIR reduced the transcription of IL-1β and IL-6, respectively, whereas MIST attenuated TNFα production posttranscriptionally. In addition, we showed that reengineered GAPLINC reduced LPS-induced inflammation in human monocytes, suggesting the clinical potential of this approach. Our engineering approach and findings establish a previously unidentified nucleic acid modality and demonstrate an effective way to reengineer regulatory lncRNAs to treat disease.
- Open Access
The Clearance of Human Cytomegalovirus Using CRISPR/Cas9 RNA Lipid Nanoparticles
Human cytomegalovirus (HCMV), a DNA virus, poses significant health risks to immunocompromised and immunosuppressed individuals and newborns. Clinical antiviral drugs like ganciclovir inhibit viral replication but have toxicities, are ineffective against drug-resistant strains, and cannot destroy HCMV DNA. CRISPR/Cas9 can cleave DNA, but has not been used therapeutically to target and degrade HCMV DNA in cells post-infection. We developed an all-in-one CRISPR/Cas9 RNA lipid nanoparticle (LNP) that clears established HCMV infections, permits rapid updating to combat resistance and is effective against multiple strains. Bioinformatic analyses identified essential, conserved viral genes as CRISPR/Cas9 targets. A delivery material screen revealed that antiviral activity was dependent on the ionizable lipid and LNP composition. Our lead formulation, βN2-40, inhibited up to 93.5% of HCMV infection with a single treatment. Furthermore, multitargeting βN2-40 LNPs demonstrated antiviral kinetics and a safety profile similar to ganciclovir, making it a compelling alternative to existing small-molecule antiviral drugs.
Open AccessThe Clearance of Human Cytomegalovirus Using CRISPR/Cas9 RNA Lipid Nanoparticles
Human cytomegalovirus (HCMV), a DNA virus, poses significant health risks to immunocompromised and immunosuppressed individuals and newborns. Clinical antiviral drugs like ganciclovir inhibit viral replication but have toxicities, are ineffective against drug-resistant strains, and cannot destroy HCMV DNA. CRISPR/Cas9 can cleave DNA, but has not been used therapeutically to target and degrade HCMV DNA in cells post-infection. We developed an all-in-one CRISPR/Cas9 RNA lipid nanoparticle (LNP) that clears established HCMV infections, permits rapid updating to combat resistance and is effective against multiple strains. Bioinformatic analyses identified essential, conserved viral genes as CRISPR/Cas9 targets. A delivery material screen revealed that antiviral activity was dependent on the ionizable lipid and LNP composition. Our lead formulation, βN2-40, inhibited up to 93.5% of HCMV infection with a single treatment. Furthermore, multitargeting βN2-40 LNPs demonstrated antiviral kinetics and a safety profile similar to ganciclovir, making it a compelling alternative to existing small-molecule antiviral drugs.
- 18 October 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (43) , 17128-17134
A Cell-Free Kinetic Analysis of Ionizable Lipid Hydrolysis
The prolonged retention of ionizable lipids within the body limits the repeated dosing of lipid nanoparticles (LNPs) for nucleic acid delivery. While most ionizable lipids are primarily metabolized in the liver via the enzymatic hydrolysis of ester bonds, elimination half-lives can range from several hours to days. The development of compounds that undergo rapid biodegradation remains a major engineering challenge in the absence of standardized biodegradability assessments in the early stages of drug discovery. Here, we analyze and compare the hydrolysis kinetics of well-known ionizable lipids (ALC-0315, DLin-MC3-DMA, LP-01, L319, and SM-102) using optimized cell-free reactions monitored by 1H NMR. Unlike conventional analytical techniques, these NMR-based methods are universal and suitable for high-throughput screening. We demonstrate that enzyme-catalyzed and base hydrolysis reactions can predict whether ionizable lipids undergo fast or slow liver elimination, as our results are in alignment with prior pharmacokinetic studies. Furthermore, we show that the hydrolysis kinetics of ionizable lipids vary by several orders of magnitude depending on steric effects. This study provides a framework to expedite the discovery of rapidly degradable ionizable lipids, with implications for improving the therapeutic index of LNP-based drugs.
- 18 October 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (43) , 17128-17134
A Cell-Free Kinetic Analysis of Ionizable Lipid Hydrolysis
The prolonged retention of ionizable lipids within the body limits the repeated dosing of lipid nanoparticles (LNPs) for nucleic acid delivery. While most ionizable lipids are primarily metabolized in the liver via the enzymatic hydrolysis of ester bonds, elimination half-lives can range from several hours to days. The development of compounds that undergo rapid biodegradation remains a major engineering challenge in the absence of standardized biodegradability assessments in the early stages of drug discovery. Here, we analyze and compare the hydrolysis kinetics of well-known ionizable lipids (ALC-0315, DLin-MC3-DMA, LP-01, L319, and SM-102) using optimized cell-free reactions monitored by 1H NMR. Unlike conventional analytical techniques, these NMR-based methods are universal and suitable for high-throughput screening. We demonstrate that enzyme-catalyzed and base hydrolysis reactions can predict whether ionizable lipids undergo fast or slow liver elimination, as our results are in alignment with prior pharmacokinetic studies. Furthermore, we show that the hydrolysis kinetics of ionizable lipids vary by several orders of magnitude depending on steric effects. This study provides a framework to expedite the discovery of rapidly degradable ionizable lipids, with implications for improving the therapeutic index of LNP-based drugs.
- Open Access
Engineering ionizable lipids for rapid biodegradation balances mRNA vaccine efficacy and tolerability
The optimization of lipid nanoparticles (LNPs) has played a key role in enhancing the efficacy of mRNA vaccines, yet challenges with LNP tolerability remain. The ionizable lipid component within LNPs is critical to the efficient delivery of mRNA. Ionizable lipids can also trigger innate immune activation, which is beneficial for vaccine efficacy but may contribute to adverse inflammatory reactions. Engineering ionizable lipids for rapid biodegradation is a promising, yet underexplored, strategy to dampen inflammation. Here, we report the rational design and optimization of biodegradable ionizable lipids for intramuscular mRNA vaccines in mice. We show that in vivo biodegradability is enhanced by controlling lipid hydrolysis kinetics and that protein output is maximized by tuning the LNP apparent pK a . In an influenza vaccine model, the lead lipid (δO3) generates equivalent neutralizing antibodies and stronger antigen-specific T cell responses compared to a benchmark lipid (SM-102) used in approved mRNA vaccines. Furthermore, by comparing ionizable lipid analogs with similar potency but opposing biodegradation kinetics, we find that faster lipid clearance from tissues coincides with a lower inflammatory response while preserving strong vaccine immunogenicity. These findings demonstrate that fast-degrading ionizable lipids can balance the efficacy and tolerability of mRNA vaccines, with implications for addressing side effects and patient acceptance of new vaccine applications.
Open AccessEngineering ionizable lipids for rapid biodegradation balances mRNA vaccine efficacy and tolerability
The optimization of lipid nanoparticles (LNPs) has played a key role in enhancing the efficacy of mRNA vaccines, yet challenges with LNP tolerability remain. The ionizable lipid component within LNPs is critical to the efficient delivery of mRNA. Ionizable lipids can also trigger innate immune activation, which is beneficial for vaccine efficacy but may contribute to adverse inflammatory reactions. Engineering ionizable lipids for rapid biodegradation is a promising, yet underexplored, strategy to dampen inflammation. Here, we report the rational design and optimization of biodegradable ionizable lipids for intramuscular mRNA vaccines in mice. We show that in vivo biodegradability is enhanced by controlling lipid hydrolysis kinetics and that protein output is maximized by tuning the LNP apparent pK a . In an influenza vaccine model, the lead lipid (δO3) generates equivalent neutralizing antibodies and stronger antigen-specific T cell responses compared to a benchmark lipid (SM-102) used in approved mRNA vaccines. Furthermore, by comparing ionizable lipid analogs with similar potency but opposing biodegradation kinetics, we find that faster lipid clearance from tissues coincides with a lower inflammatory response while preserving strong vaccine immunogenicity. These findings demonstrate that fast-degrading ionizable lipids can balance the efficacy and tolerability of mRNA vaccines, with implications for addressing side effects and patient acceptance of new vaccine applications.
- Top Cited Papers
- 18 January 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (4) , 2294-2304
Iterative Design of Ionizable Lipids for Intramuscular mRNA Delivery
Lipid nanoparticles (LNPs) are the most clinically advanced delivery vehicles for RNA and have enabled the development of RNA-based drugs such as the mRNA COVID-19 vaccines. Functional delivery of mRNA by an LNP greatly depends on the inclusion of an ionizable lipid, and small changes to these lipid structures can significantly improve delivery. However, the structure-function relationships between ionizable lipids and mRNA delivery are poorly understood, especially for LNPs administered intramuscularly. Here, we show that the iterative design of a novel series of ionizable lipids generates key structure-activity relationships and enables the optimization of chemically distinct lipids with efficacy that is on-par with the current state of the art. We find that the combination of ionizable lipids comprising an ethanolamine core and LNPs with an apparent pKa between 6.6 and 6.9 maximizes intramuscular mRNA delivery. Furthermore, we report a nonlinear relationship between the lipid-to-mRNA mass ratio and protein expression, suggesting that a critical mass ratio exists for LNPs and may depend on ionizable lipid structure. Our findings add to the mechanistic understanding of ionizable lipids and demonstrate that hydrogen bonding, ionization behavior, and lipid-to-mRNA mass ratio are key design parameters affecting intramuscular mRNA delivery. We validate these insights by applying them to the rational design of new ionizable lipids. Overall, our iterative design strategy efficiently generates potent ionizable lipids. This hypothesis-driven method reveals structure-activity relationships that lay the foundation for the optimization of ionizable lipids in future LNP-RNA drugs. We foresee that this design strategy can be extended to other optimization parameters beyond intramuscular expression.
- 18 January 2023
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 145 (4) , 2294-2304
Top Cited PapersIterative Design of Ionizable Lipids for Intramuscular mRNA Delivery
Lipid nanoparticles (LNPs) are the most clinically advanced delivery vehicles for RNA and have enabled the development of RNA-based drugs such as the mRNA COVID-19 vaccines. Functional delivery of mRNA by an LNP greatly depends on the inclusion of an ionizable lipid, and small changes to these lipid structures can significantly improve delivery. However, the structure-function relationships between ionizable lipids and mRNA delivery are poorly understood, especially for LNPs administered intramuscularly. Here, we show that the iterative design of a novel series of ionizable lipids generates key structure-activity relationships and enables the optimization of chemically distinct lipids with efficacy that is on-par with the current state of the art. We find that the combination of ionizable lipids comprising an ethanolamine core and LNPs with an apparent pKa between 6.6 and 6.9 maximizes intramuscular mRNA delivery. Furthermore, we report a nonlinear relationship between the lipid-to-mRNA mass ratio and protein expression, suggesting that a critical mass ratio exists for LNPs and may depend on ionizable lipid structure. Our findings add to the mechanistic understanding of ionizable lipids and demonstrate that hydrogen bonding, ionization behavior, and lipid-to-mRNA mass ratio are key design parameters affecting intramuscular mRNA delivery. We validate these insights by applying them to the rational design of new ionizable lipids. Overall, our iterative design strategy efficiently generates potent ionizable lipids. This hypothesis-driven method reveals structure-activity relationships that lay the foundation for the optimization of ionizable lipids in future LNP-RNA drugs. We foresee that this design strategy can be extended to other optimization parameters beyond intramuscular expression.
- 21 November 2022
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 19 (12) , 1650-1663
The engineering challenges and opportunities when designing potent ionizable materials for the delivery of ribonucleic acids
Ionizable lipids are critical components in lipid nanoparticles. These molecules sequester nucleic acids for delivery to cells. However, to build more efficacious delivery molecules, the field must...
- 21 November 2022
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 19 (12) , 1650-1663
The engineering challenges and opportunities when designing potent ionizable materials for the delivery of ribonucleic acids
Ionizable lipids are critical components in lipid nanoparticles. These molecules sequester nucleic acids for delivery to cells. However, to build more efficacious delivery molecules, the field must...
- Top Cited Papers
- 10 August 2020
- Published by Springer Nature in Nature Materials
- Vol. 19 (12) , 1362-1371
The dose threshold for nanoparticle tumour delivery
Nanoparticle delivery to solid tumours over the past ten years has stagnated at a median of 0.7% of the injected dose. Varying nanoparticle designs and strategies have yielded only minor improvements. Here we discovered a dose threshold for improving nanoparticle tumour delivery: 1 trillion nanoparticles in mice. Doses above this threshold overwhelmed Kupffer cell uptake rates, nonlinearly decreased liver clearance, prolonged circulation and increased nanoparticle tumour delivery. This enabled up to 12% tumour delivery efficiency and delivery to 93% of cells in tumours, and also improved the therapeutic efficacy of Caelyx/Doxil. This threshold was robust across different nanoparticle types, tumour models and studies across ten years of the literature. Our results have implications for human translation and highlight a simple, but powerful, principle for designing nanoparticle cancer treatments.
- 10 August 2020
- Published by Springer Nature in Nature Materials
- Vol. 19 (12) , 1362-1371
Top Cited PapersThe dose threshold for nanoparticle tumour delivery
Nanoparticle delivery to solid tumours over the past ten years has stagnated at a median of 0.7% of the injected dose. Varying nanoparticle designs and strategies have yielded only minor improvements. Here we discovered a dose threshold for improving nanoparticle tumour delivery: 1 trillion nanoparticles in mice. Doses above this threshold overwhelmed Kupffer cell uptake rates, nonlinearly decreased liver clearance, prolonged circulation and increased nanoparticle tumour delivery. This enabled up to 12% tumour delivery efficiency and delivery to 93% of cells in tumours, and also improved the therapeutic efficacy of Caelyx/Doxil. This threshold was robust across different nanoparticle types, tumour models and studies across ten years of the literature. Our results have implications for human translation and highlight a simple, but powerful, principle for designing nanoparticle cancer treatments.